Glossary

A molecule that binds to a receptor and activates it, mimicking the action of the endogenous ligand. Full agonists produce maximal receptor activation; partial agonists produce submaximal responses even at saturating concentrations.

A regulatory mechanism where ligand binding at one site affects activity at a distant site through conformational changes. Described by MWC (concerted) and KNF (sequential) models.

A right-handed coiled secondary structure element where each backbone N–H forms a hydrogen bond with the C=O of the residue four positions earlier, creating 3.6 residues per turn with a pitch of 5.4 Å.

The linear order of amino acid residues in a polypeptide chain, read from the N-terminus to the C-terminus. This primary structure encodes all information necessary for a protein to fold into its functional three-dimensional conformation.

Insoluble fibrous protein aggregates with a characteristic cross-β sheet structure where β-strands run perpendicular to the fibril axis. Associated with diseases like Alzheimer's and Parkinson's.

A molecule that binds to a receptor without activating it, blocking the binding and action of agonists. Competitive antagonists compete for the same binding site; non-competitive antagonists bind allosteric sites.

A catabolic process where cellular components are sequestered in double-membrane vesicles (autophagosomes) and delivered to lysosomes for degradation and recycling.

Sterile water containing 0.9% benzyl alcohol as a preservative that inhibits bacterial growth. Commonly used as a solvent for reconstituting lyophilized peptides, allowing multi-dose use from a single vial.

A secondary structure element composed of extended polypeptide strands (β-strands) linked laterally by backbone hydrogen bonds. Strands can run in the same direction (parallel) or opposite directions (antiparallel).

An experimental procedure that measures the biological activity of a substance by observing its effect on living cells, tissues, or organisms. Used to quantify peptide potency, validate activity, and compare batches.

The fraction of an administered dose of a substance that reaches systemic circulation in an unchanged form. Oral bioavailability of peptides is typically low due to enzymatic degradation and poor membrane permeability.

A regulatory standard demonstrating that two formulations of the same active substance produce comparable bioavailability and pharmacokinetic profiles, ensuring they can be used interchangeably.

A membrane-less compartment formed by liquid-liquid phase separation that concentrates specific proteins and nucleic acids to organize biochemical reactions.

The end of a peptide or protein chain bearing a free carboxyl group (–COOH). Post-translational amidation of the C-terminus is common in bioactive peptides and can enhance receptor binding and stability.

A protein that assists in the folding, unfolding, or assembly of other proteins without being part of the final structure. Examples include Hsp70, Hsp90, and chaperonins like GroEL/ES.

A selective autophagy pathway where proteins bearing a KFERQ-like motif are recognized by Hsc70 and translocated directly across the lysosomal membrane via LAMP2A.

The volume of plasma from which a drug is completely removed per unit time, reflecting the body's efficiency at eliminating the compound. Total clearance is the sum of renal, hepatic, and other elimination pathways.

A document issued by a manufacturer or testing laboratory that certifies the identity, purity, and quality of a peptide product. Typically includes HPLC purity data, mass spectrometry confirmation, and endotoxin levels.

The collection of all thermally accessible conformations a protein can adopt, weighted by their Boltzmann probabilities. Essential for understanding IDPs and dynamic proteins.

The formation of a cyclic structure in a peptide by covalent bond formation between two points in the chain, such as head-to-tail, side chain-to-side chain, or disulfide bridges. Cyclization often improves metabolic stability and receptor selectivity.

A covalent bond between cysteine thiol groups that stabilizes protein structure. Forms in oxidizing environments like the ER; critical for secreted and membrane protein stability.

A graphical representation of the relationship between the dose of a substance and the magnitude of its biological effect. Sigmoidal curves are fit to determine EC50, Emax, and Hill coefficient parameters.

The half-maximal effective concentration — the concentration of an agonist that produces 50% of its maximal possible effect. Used to quantify potency and compare efficacy across compounds.

Assays to detect bacterial lipopolysaccharide (LPS) contamination in pharmaceutical products. The Limulus Amebocyte Lysate (LAL) test is the gold standard, with acceptable limits typically below 5 EU/kg for injectable peptides.

An amino acid that cannot be synthesized by an organism and must be obtained from the diet. In humans: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.

The rapid metabolism of an orally administered compound by gut wall enzymes and hepatic enzymes before it reaches systemic circulation. A major barrier to oral peptide delivery, often reducing bioavailability below 1–2%.

A solid-phase peptide synthesis strategy using the 9-fluorenylmethoxycarbonyl (Fmoc) group as a temporary α-amino protecting group, removable under mild basic conditions (piperidine). The most widely used approach in modern SPPS.

Also known as GHS-R1a (growth hormone secretagogue receptor type 1a), a GPCR that binds ghrelin and synthetic secretagogues. Activation stimulates appetite, growth hormone release, and reward signaling in the brain.

A G protein-coupled receptor activated by glucagon-like peptide-1. Expressed on pancreatic beta cells, neurons, and other tissues, it stimulates insulin secretion, suppresses glucagon, and promotes satiety. The target of semaglutide and liraglutide.

The attachment of carbohydrate chains to proteins. N-linked glycosylation occurs at asparagine residues; O-linked at serine/threonine. Critical for protein folding, stability, and recognition.

A class of compounds that stimulate growth hormone release from the anterior pituitary, often by activating the ghrelin receptor (GHS-R1a). Includes peptides like GHRP-6, hexarelin, and ipamorelin.

The time required for the concentration of a substance in the body to decrease by half. Peptide half-lives range from minutes to hours and can be extended through pegylation, lipidation, or formulation strategies.

An analytical and preparative technique that separates compounds in a liquid mixture by pumping them at high pressure through a column packed with adsorbent material. Reverse-phase HPLC is the standard method for assessing peptide purity.

An electrostatic attraction between a hydrogen atom covalently bonded to an electronegative donor (N or O) and a nearby acceptor atom. Hydrogen bonds stabilize secondary structure, mediate specificity in molecular recognition, and maintain water structure.

A technique measuring the rate of backbone amide hydrogen exchange with deuterium to probe protein dynamics, folding, and ligand-induced conformational changes.

The thermodynamic driving force that causes nonpolar molecules to aggregate in aqueous solution, minimizing their disruption of the water hydrogen-bonding network. The dominant force in protein folding, driving burial of hydrophobic side chains in the protein core.

The half-maximal inhibitory concentration — the concentration of an inhibitor required to reduce a biological response by 50%. A key metric for comparing potency of antagonists and enzyme inhibitors.

Experiments performed outside a living organism, typically in cell cultures, test tubes, or other controlled laboratory environments. In vitro assays are used to screen peptide activity before advancing to animal studies.

Experiments performed within a living organism, providing data on absorption, distribution, metabolism, excretion, and pharmacological effects that cannot be captured in cell-based systems alone.

Administration of a substance directly into skeletal muscle tissue, providing a depot from which the compound is gradually absorbed into systemic circulation. Offers faster absorption than subcutaneous injection for many peptides.

Delivery of a substance through the nasal mucosa, providing a non-invasive route that can bypass the blood-brain barrier for certain peptides. Used for peptides like oxytocin and desmopressin.

A protein or protein region that lacks a stable three-dimensional structure under physiological conditions, yet performs essential biological functions through conformational flexibility.

The demixing of a solution into coexisting dense and dilute liquid phases, driven by multivalent interactions. Forms membraneless organelles like stress granules and nucleoli.

A freeze-drying process that removes water from a peptide solution under vacuum, producing a stable powder with extended shelf life. The process preserves molecular structure better than conventional drying methods.

An analytical technique that measures mass-to-charge ratios of ions. In proteomics, used for protein identification, sequencing, and PTM characterization via techniques like ESI and MALDI.

A family of five G protein-coupled receptors (MC1R–MC5R) activated by melanocortin peptides derived from POMC. They regulate pigmentation, energy homeostasis, inflammation, and sexual function.

A compact, partially folded protein intermediate with native-like secondary structure but lacking fixed tertiary contacts. It represents a kinetic waypoint on the folding pathway.

The end of a peptide or protein chain bearing a free amino group (–NH₂). By convention, amino acid sequences are written and synthesized starting from the N-terminus. Also called the amino terminus.

A small protein-like molecule produced and released by neurons to act as intercellular signaling molecules. Examples include substance P, neuropeptide Y, oxytocin, and vasopressin. They modulate pain, mood, appetite, and cognition.

Large modular enzymes that synthesize peptides independently of ribosomes using an assembly-line logic. Each module incorporates one amino acid, including non-proteinogenic ones.

The rate-limiting formation of initial aggregation seeds (nuclei) from which amyloid fibrils can rapidly elongate. Can be primary (spontaneous) or secondary (fibril-catalyzed).

The covalent attachment of polyethylene glycol (PEG) chains to a peptide or protein. Pegylation increases hydrodynamic radius, reduces renal clearance, shields from proteolysis, and significantly extends circulating half-life.

The covalent amide bond linking amino acids in proteins. Has partial double-bond character due to resonance, restricting rotation and favoring planar trans geometry.

The percentage of the target peptide relative to total peptide-related material in a sample, typically determined by analytical HPLC. Research-grade peptides are usually ≥95% pure; higher purities are required for in vivo studies.

The study of how a drug affects the body, including mechanism of action, dose-response relationships, and therapeutic and adverse effects. Complements pharmacokinetics to provide a full drug activity profile.

The study of how the body affects a drug over time, encompassing absorption, distribution, metabolism, and excretion (ADME). Determines dosing regimens and predicts plasma concentration profiles.

The first stage of human testing for a new therapeutic, focused on safety, tolerability, pharmacokinetics, and dose-finding in a small cohort of healthy volunteers or patients. Typically enrolls 20–100 subjects.

The addition of a phosphate group to serine, threonine, or tyrosine residues by kinases. A reversible modification central to cell signaling and metabolic regulation.

The reversible binding of a drug to plasma proteins, primarily albumin and α1-acid glycoprotein. Only the unbound fraction is pharmacologically active; high protein binding serves as a drug reservoir and extends half-life.

Modular enzymes that synthesize polyketide natural products through iterative Claisen condensations, analogous to fatty acid synthesis but with variable reduction states.

Chemical modifications to proteins after translation, including phosphorylation, acetylation, ubiquitination, and glycosylation. PTMs regulate protein function, localization, and interactions.

Research conducted before human trials to evaluate a compound's safety profile, pharmacology, and toxicology. Includes in vitro assays, animal models, and ADME studies required for regulatory submissions.

The linear sequence of amino acids in a polypeptide chain, connected by peptide bonds. This first level of protein organization encodes all the information required for higher-order folding and function.

A misfolded protein that can induce normal variants of the same protein to adopt the pathological conformation, creating a self-propagating infectious agent without nucleic acids.

A large protein complex (26S) that degrades ubiquitinated proteins. The 20S core has proteolytic activity; 19S regulatory caps recognize substrates and unfold them for degradation.

The arrangement and interaction of multiple protein subunits to form a functional complex. Hemoglobin's α₂β₂ tetramer is a classic example.

A two-dimensional plot of backbone dihedral angles (φ, ψ) showing sterically allowed conformations. Different regions correspond to α-helices, β-sheets, and other structures.

A measure of the strength of interaction between a ligand and its receptor, typically expressed as the dissociation constant (Kd). Lower Kd values indicate higher affinity. Determined by radioligand binding assays or surface plasmon resonance.

The process of dissolving a lyophilized peptide powder in a suitable solvent, typically bacteriostatic water or sterile water, to prepare it for use. Proper reconstitution technique preserves peptide integrity.

Ribosomally synthesized and Post-translationally modified Peptides. A class of natural products where a ribosomal precursor peptide undergoes extensive enzymatic modifications.

Local, regularly repeating conformations of the polypeptide backbone stabilized by hydrogen bonds between backbone amide and carbonyl groups. The two major types are α-helices and β-sheets.

The process by which pre-formed aggregates (seeds) template the misfolding of native proteins, bypassing the lag phase of spontaneous nucleation.

A short, degenerate peptide sequence (3-10 residues) typically found in intrinsically disordered regions that mediates protein-protein interactions and regulatory functions.

A method for chemical peptide synthesis where the growing chain is anchored to an insoluble resin, enabling iterative coupling and deprotection cycles with simple washing steps.

The condition where the rate of drug administration equals the rate of elimination, resulting in stable plasma concentrations. Typically achieved after approximately 4–5 half-lives of repeated dosing.

Microbiological testing to confirm the absence of viable microorganisms in a product. Required for injectable peptide preparations, performed by membrane filtration or direct inoculation into growth media per pharmacopeial standards.

Administration of a substance into the layer of tissue between the skin and muscle (subcutis). A common route for peptide delivery that provides slower, more sustained absorption compared to intravenous administration.

The overall three-dimensional arrangement of all atoms in a single polypeptide chain, resulting from interactions between secondary structural elements, side chains, and the solvent. Determines the protein's functional shape.

The ratio of the toxic dose to the therapeutic dose (TD50/ED50), quantifying a drug's safety margin. A narrow therapeutic index means small dosing changes can cause toxicity or loss of efficacy.

The covalent attachment of ubiquitin to lysine residues via an E1-E2-E3 enzymatic cascade. K48-linked chains target proteins for proteasomal degradation; K63-linked chains regulate signaling.

Weak, short-range attractive forces arising from transient dipole interactions between atoms. In proteins, the cumulative effect of thousands of Van der Waals contacts contributes significantly to structural stability and molecular recognition.

A theoretical pharmacokinetic parameter (Vd) relating the total amount of drug in the body to its plasma concentration. Large Vd indicates extensive tissue distribution; small Vd suggests confinement to the vascular compartment.

A molecule with both positive and negative charges at physiological pH. Amino acids exist as zwitterions with protonated amino groups (NH₃⁺) and deprotonated carboxyl groups (COO⁻).